The Current Status and Prospects of Mesenchymal Stem Cells in Targeted Therapy for Premature Ovarian Insufficiency
LIU Qiang1,2*, LIU Huaqian1, LIU Li1, WANG Liming1
POI (premature ovarian insufficiency), also previously known as POF (premature ovarian fail ure), is a complex endocrine disease, which is common in women under 40 years old. Its characteristic is that the ovarian function stops before the age of 40, which has a greater impact on the female’s physiology and psychology, and the biggest influence is to lead to infertility. At present, the methods that can be used to treat POI are limited, and the effect is often not good. Stem cell transplantation is a new method for the treatment of POI studied by schol ars at home and abroad in recent years. Especially for female with POI in need of reprodution, stem cell therapy is the ultimate choice. To date, the most mature stem cell therapy for POI therapy is MSCs (mesenchymal stem cells), and its efficacy has been confirmed by preclinical and clinical studies. Tissue engineering and stem cell therapy strategies have become promising methods to restore ovarian function and improve the quality of life of female with POI. This review aims to comprehensively review the research status of POI, focusing on the progress and development prospect of MSCs from different sources for clinical application to treat POI, which includes efficacy of MSCs derived from bone marrow, umbilical cord, adipose and menstrual blood after minimally invasive targeted therapy, and the comparison of ovarian function recovery between different sources of MSCs. Additionally, this pa per discusses the development of biomaterials and scaffolds that mimic the natural ovarian microenvironment and support the growth and maturation of ovarian cells and follicles. Furthermore, the review highlights the challenges and ethical considerations associated with tissue engineering and stem cell-based therapies for POI, and proposes potential solutions to address these issues.
CN
EN